Connect with us


Is the Trump-China Trade War Making It Tough for Cannabis Businesses to Survive?

Jane Summers



How the U.S.-China Trade War is Affecting the Cannabis Industry – and How You Can Avoid the 25% Tariff
- Ad -

Ever since President Donald Trump announced entering a trade war with China, many businesses and consumers have been very watchful of how it might all play out. So far, news outlet Forbes, who referenced CNBC, noted that there’s, “25 percent tariffs levied on $200 billions of Chinese goods,” with more goods expected to be taxed some more.

Ever since the announcement was made, nearly 50 American businesses have opted out of conducting production operations in China. This being said, it has been argued that the cannabis industry might be stuck in a sticky situation.

According to the news outlet, CEO of cannabis firm, Aster Farms, Julia Jacobson, shared that the 25 percent tariffs made it relatively tough to conduct her business operations on a timely basis. Given that her company relies on the Chinese for the company’s packaging, most orders eventually got backed up until she was able to pay the tariffs. In particular, she said:

“Our custom tins for our pre-roll pack were finished, but not shipped when the tariffs first kicked in. It resulted in our shipment being delayed for two months and was only released after we paid an additional 25 percent.”

As for the reason why she retorts to China, the current regulations on cannabis packaging forced her to seek said needs elsewhere. This is interesting to hear, as China is neither for the use of cannabis, nor does it believe it testing. Nonetheless, she further made the case that,

“While many people think the cannabis industry is striking it rich, with the current regulations […] we are all operating on extremely thin and often negative margins.”

Does this mean that all cannabis firms are suffering? Perry N. Salzhauer, a lawyer at Green Light Law Group was referenced saying that his clients aren’t entirely affected. He reasons that,

“It’s possible that the ordering of the equipment is bypassing some of the tariff system,” he speculated. “It must be under the radar. They’re not going through customs or [U.S. cannabis firms] are directly ordering these things from a company in China. That’s a totally different can of worms because that can be subject to the postal office.”

A news report by Forbes further indicates that”For companies like Aster Farms that are feeling the effects of the tariffs, little can be done. [T]he proverbial banking problem faced by many marijuana businesses [is] an obstacle rooted in the federal illegality of the substance.” Because cannabis is illegal under federal law, cannabis companies operating in states that have legalized the substance still face significant risks and challenges.

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.